The Food and Drug Administration (FDA) has granted approval for the distribution of more than 800,000 doses of JYNNEOS monkeypox vaccination, which is paving the way for a needed expansion of quantity at a time that the outbreak of monkeypox is fueling the demand for jabs in males who have had sexual relations with males.
In a series tweets that were posted on July 27th in which the FDA announced that they had granted approval to “a supplement to the biologics” for the JYNNEOS vaccine, following an inspection of the plant earlier in the month, and completing an evaluation of the product’s quality.
The increase in doses is a result of news reports that stated that thousands of doses imported from Denmark were delayed due to regulatory and inspection hurdles. In the words of the FDA further doses have arrived since being shipped in America. United States.
“With this supplement approval, those manufactured doses may now be further distributed and administered,” the FDA tweeted. “Additional doses made in this plant could aid in addressing the need for this vaccine in the future..
The cases of monkeypox continue to increase across the globe and in those of the United States. At the time of writing the CDC recorded 4,639 cases of monkeypox across the nation -as well as in the New York City Department of Health and Mental Hygiene has recorded 1,148 cases at the time of July 27.
“This action by the FDA is a critical step forward in our plans to strengthen and accelerate our monkeypox response, which includes distributing a safe and effective vaccine to those at highest risk of exposure to monkeypox,” US Health and Human Services Secretary Xavier Becerra said in a written statement. “The expedited inspection and approval by FDA of Bavarian Nordic’s fill-and-finish capabilities means that an additional 786,000 doses of vaccine are now available for use in the U.S.”
The World Health Organization declared monkeypox an international urgent situation the 23rd of July, and homosexual Congressmember Ritchie Torres of the Bronx introduced a resolution on July 26, urging HHS to declare an emergency of public health in the United States due to monkeypox. Two more members from Congress supported the resolution, which included out-of-gay lawmakers Mondaire Jones from New York, Mark Takano of California along with Mark Pocan of Wisconsin.
People who qualify to receive the vaccine for monkeypox within New York City include men who have had sexual relations with men and transgenders, gender non-conforming and non-binary persons who are 18 or more years old and who have been involved in multiple or anonymous sex partners over the past two weeks. It is recommended that the Health Department also recommends vaccination to anyone who has had a close relationship with the person who has monkeypox.
The shortage of vaccines has led certain cities — like New York, San Francisco and Washington, DC — to concentrate, at present on the first dose from the double-dose Jynneos regimen that is usually administered every 28 days.
Monkeypox is most prevalent among males who have sex with other males. On the 19th of July, males accounted for 97.7 percent of cases of monkeypox within New York City, while transgender, gender non-conforming and non-binary people comprised 1.4 percent of cases. One woman was positive for the virus monkeypox.
Between 30 and 39 aged accounted for the highest percentage of cases, averaging 50percent. More than half of cases involving New York City (54 percent) originated from Manhattan and was then followed by Brooklyn (21.6 percent). Queens (12.4%), the Bronx (11.4%), and Staten Island (0.5%). White people led the way with 31% of cases, while Hispanic/Latino folks made up 21.4% of cases and Black/African-American folks represented 17.2%. The only 3.4 percent of cases occurred from Asian/Pacific Islander people and 26.6 percent were not known.
Further announcements are expected on the 28th of July regarding the distribution of vaccine doses all over the country, Becerra added.